Joseph Monahan - 05 May 2021 Form 3 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Mark Ballantyne, as Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
05 May 2021
Net transactions value
$0
Form type
3
Filing time
17 May 2021, 18:06:01 UTC
Next filing
02 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACRS Common Stock 57,132 05 May 2021 Direct
holding ACRS Common Stock 193 05 May 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRS Employee Stock Option (Right to Buy) 05 May 2021 Common Stock 56,000 $25.80 Direct F1
holding ACRS Employee Stock Option (Right to Buy) 05 May 2021 Common Stock 14,700 $22.09 Direct F2
holding ACRS Restricted Stock Units 05 May 2021 Common Stock 2,333 Direct F3, F4
holding ACRS Restricted Stock Units 05 May 2021 Common Stock 1,050 Direct F4, F5
holding ACRS Restricted Stock Units 05 May 2021 Common Stock 27,500 Direct F4, F6
holding ACRS Restricted Stock Units 05 May 2021 Common Stock 50,000 Direct F4, F7
holding ACRS Restricted Stock Units 05 May 2021 Common Stock 37,500 Direct F4, F8
holding ACRS Restricted Stock Units 05 May 2021 Common Stock 200,000 Direct F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a period of four years. 75% of the shares are currently vested with the remaining 25% vesting on September 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F2 The option vests over a period of four years. 75% of the shares are currently vested with the remaining 25% vesting on February 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option.
F3 The shares underlying these restricted stock units vest on September 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F4 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F5 The shares underlying these restricted stock units vest on February 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F6 The shares underlying these restricted stock units vest over a period of two years, with 50% vesting on March 1, 2022 and 50% vesting on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F7 The shares underlying these restricted stock units vest on June 1, 2021, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F8 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 2, 2022, March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
F9 The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on March 1, 2022, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney